Systematic Review of the Safety of the Heart Rate Lowering Drug Ivabradine

Abstract

Abstract: Objective To evaluate the safety of ivabradine in decreasing heart rate. Methods The randomized controlled trials of ivabradine in decreasing heart rate, which had been published from the time of library foundation to October, 2017 were collected from Pubmed, CNKI database according to the including criteria. The results of studies were analyzed through Stata 14.1 software and Rev Man 5.3 software. Results Ten randomized controlled trials were included. Meta-analysis showed that there was significant difference between ivabradine and controls in bradycardia (RR=4.16, 95% CI: 2.61-6.63, I²=92%, P<0.00001) and phosphenes (RR=5.07, 95% CI: 3.31-7.77, I²=68%, P <0.00001). Conclusion Meta-analysis proved that ivabradine was associated with a significant increase in the risk of bradycardia and phosphenes. Therefore, clinicians need to take these risks into account in treatment.

Key words: ivabradine, systematic review, meta-analysis, safety

CLC Number:

JIANG Huan, WANG Yao, YAN Hong, JIANG Ying. Systematic Review of the Safety of the Heart Rate Lowering Drug Ivabradine[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 251-254.

References

[1] DiFrancesco D.Funny channels in the control of cardiac rhythm and mode of action of selective blockers[J].PHARMACOL RES, 2006, 53(5): 399-406.
[2] Tardif J C, Ford I, Tendera M,et al.Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina[J].EUR HEART J, 2005, 26(23): 2529-2536.
[3] Ruzyllo W, Tendera M, Ford I,et al.Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial[J].DRUGS, 2007, 67(3): 393-405.
[4] Amosova E, Andrejev E, Zaderey I,et al.Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina[J].Cardiovasc Drugs Ther, 2011, 25(6): 531-537.
[5] Swedberg K, Komajda M, Bohm M,et al.Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J].LANCET, 2010, 376(9744): 875-885.
[6] US. Food and Drug Administration. CORLANOR (ivabradine) safely and effectively[EB/OL]. (2015-04-15)[2017-10-15]. https://www.fda.gov/Drugs/.
[7] . Martin R I, Pogoryelova O, Koref MS,et al.Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials[J].HEART, 2014, 100(19): 1506-1510.
[8] The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0[M/OL]. (2011-03-01)[2017-10-15]. http://handbook.cochrane.org/.
[9] Fox K, Ford I, Steg P G,et al.Ivabradine in stable coronary artery disease without clinical heart failure[J].N Engl J Med, 2014, 371(12): 1091-1099.
[10] Celik O, Atasoy M M, Erturk M,et al.Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy[J].ACTA RADIOL, 2014, 55(6): 676-681.
[11] Pichler P, Pichler-Cetin E, Vertesich M,et al.Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography[J].AM J CARDIOL, 2012, 109(2): 169-173.
[12] Fasullo S, Cannizzaro S, Maringhini G,et al.Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings[J].J CARD FAIL, 2009, 15(10): 856-863.
[13] Tardif J C, Ponikowski P, Kahan T.Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial[J].EUR HEART J, 2009, 30(5): 540-548.
[14] Fox K, Ford I, Steg P G,et al.Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial[J].LANCET, 2008, 372(9641): 807-816.
[15] Borer J S, Fox K, Jaillon P,et al.Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial[J].CIRCULATION, 2003, 107(6): 817-823.
[16] McMurray J J, Adamopoulos S, Anker S D,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J].EUR J HEART FAIL, 2012, 14(8): 803-869.
[17] Montalescot G, Sechtem U, Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J].EUR HEART J, 2013, 34(38): 2949-3003.
[18] Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines on the diagnosis and treatment of Heart Failure[J]. Chinese Journal of Cardiology 2014,42(2): 98-122.
[19] Yaniv Y, Sirenko S, Ziman B D,et al.New evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca(2)(+) cycling[J].J MOL CELL CARDIOL, 2013, 62: 80-89.
[20] European Medicines Agency. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)[EB/OL].(2014-11-10)[2017-10-11]. http://www.ema.europa.eu/ema/.
[21] Scicchitano P, Cortese F, Ricci G,et al.Ivabradine, coronary artery disease, and heart failure: beyond rhythm control[J].Drug Des Devel Ther, 2014, 8: 689-700.